Cambridge, United States
Neon Therapeutics, founded in 2015, is spearheading innovations in the biotechnology sector, notably through its focus on neoantigen-targeted therapies. With its slogan, "We turn cancer’s most daunting weapon into its biggest vulnerability," the company is dedicated to revolutionizing cancer treatment by stimulating the immune system to target neoantigens, a method that holds promising potential in oncology.
Headquartered in the United States, Neon Therapeutics has carved a niche in industries such as Biotechnology, Health Care, Health and Wellness, and Clean Energy. The company's innovative approach attracted a substantial $67.00M acquisition investment from BioNTech on 01 January 2020. This backing highlights their strategic alignment and confidence from leading industry players in their neoantigen-based treatments.
For investors, Neon Therapeutics represents a key player in the evolving landscape of immuno-oncology, poised to deliver transformative outcomes in cancer care.
